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Background: Biliary tree malignancies including cholangiocarcinoma and gallbladder cancer are
aggressive cancers with a high disease-specific mortality despite resection. The aim of the present study
was to identify predictors of survival after resection.
Methods: A retrospective review of all patients that underwent radical resection of biliary malignancies
was performed. Demographics, elevated CA19-9 (>35 U/ml), treatment and outcome data were collected
and compared according to tumour location. Kaplan–Meier survival curves were created and compared
using log-rank analysis. Multivariate analysis was undertaken using Cox proportional hazards regression.
Results: Ninety-one patients with biliary malignancies underwent surgical resection between 1992 and
2007. There were 46 (50.5%) extrahepatic cholangiocarcinomas (EHC), 23 (25.2%) intrahepatic cholan-
giocarcinomas (IHC) and 22 (24.2%) gallbladder carcinomas (GBC). The median (range) age was 64
(24–92) years. An elevated CA19-9 was recorded in 45 (55%) patients (52% of IHC, 63% of EHC, and
41% of GBC). The overall median (range) survival was 22.5 (0.3–153.3) months. All three groups were
similar in terms of age, gender, pre-operative CA 19-9 level, completeness of resection and tumour
histopathological characteristics. GBC were associated with the shortest median survival (14.3 months)
followed by EHC (24.8 months) and IHC (30.4 months); however, this did not meet statistical significance
(P = 0.971). Only elevated pre-operative CA 19-9 level (>35 U/ml) was predictive of poor median survival
by univariate (P = 0.003) and multivariate analysis (15.1 months vs. 67.4, P = 0.047).
Conclusions: Elevated pre-operative CA 19-9 levels were found to be independent predictors of poor
survival after attempted resection for biliary tree malignancies. It is recommended that CA19-9 be
routinely measured prior resection.
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Introduction
Biliary tree malignancies are aggressive cancers with a high
disease-specific mortality despite resection.1–4 While their inci-
dence seems to be increasing, they are still relatively uncommon,
accounting for 9520 newly diagnosed patients and 3340 deaths in
the United States in 2008.5,6 Aggressive surgical resection remains
the only hope for a cure, however, for the majority of patients
palliation remains the only option as a result of advanced state of
the disease at presentation. As such, extensive experience with
resections of such malignancies are generally lacking even in large
volume centres. The majority of existing studies are drawn either
from multi-institutional studies or cancer registries, introducing
variability of treatment and surgical techniques.2,7–10
The biliary tree contains a heterogeneous group of structures
with similar embryologic origin.11 The intrahepatic and extrahe-
patic cholangiocarcinomas are frequently compared against other
tumours of the area such as pancreatic or gallbladder cancer to
establish comparative outcomes.8,11,12 However, for the purpose of
Presented at the 9th Annual Meeting of the American Hepato-Pancreato-
Biliary Association, 12–15 March 2009, Miami, FL, USA.
DOI:10.1111/j.1477-2574.2009.00149.x HPB
HPB 2010, 12, 134–138 © 2010 International Hepato-Pancreato-Biliary Association
clinical trials comparing clinical strategies and/or the use and type
of adjuvant or neoadjuvant chemotherapy, intrahepatic and extra-
hepatic cholangiocarcinomas are often coupled with gallbladder
malignancies.13,14 The arguments for this combination are the
common embryological origin and similar biological behaviour of
these malignancies. In addition, most centres have increasing dif-
ficulty amassing a sufficient study population. This design may
increase the statistical power of the study. Finally, combining cho-
langiocarcinoma with gallbladder cancer allows for comparison
of several common variables.
The aim of the present study was to identify potential predictors
of survival for those patients who had undergone attempted cura-
tive resection for biliary tree malignancies.
Materials and methods
The study protocol was approved by the Institutional Review
Board at The Ohio State University. A retrospective case note
review of all patients who underwent resection of biliary tree
malignancies including extrahepatic cholangiocarcinoma (EHC),
intrahepatic cholangiocarcinoma (IHC), and gallbladder cancer
(GBC) between 1992 and 2007 was undertaken.
Patients were selected by retrospectively reviewing the archives
of the James Cancer Hospital tumor registry for patients diag-
nosed with biliary malignancies who subsequently underwent
surgical resection with curative intent. EHC was defined, per
National Comprehensive Cancer Network (NCCN) guidelines, as
any tumour extending from the ampulla of Vater to the hilar plate
and included hilar cholangiocarcinomas.5 IHC was defined, per
NCCN guidelines, as a tumour arising within the substance of the
liver and involving only biliary radicals above the confluence of
the right and left bile ducts.5
Patient demographics, comorbidities (defined as any chronic
disease that would potentially increase the risk of peri-operative
complications or death), presentation, treatment, histopathologi-
cal information and outcome/survival data were collected. Data
were pooled from three sources: the Ohio State University Medical
Center information warehouse, the OSU James Cancer Center
Tumor Registry and by review of patients’ electronic charts. To
assess the effect of CA19-9, a binary variable, ‘elevated CA19-9’
was defined as a value >35 U/ml. This value was chosen as this
cutoff point as it represented the upper limit of normal range.
Survival data were recorded from the time of resection until death,
as determined by the medical record and/or the social security
death index (http://ssdi.rootsweb.ancestry.com) as of 31 August
2008.
Comparisons of the three primary anatomical types were
made by anova and with contingency table analysis (c2 and
Fisher’s exact test, where appropriate). Statistical significance was
accepted at a P-value <0.05. Survival was analysed using the
Kaplan–Meier method and compared by log-rank analysis.
Serial univariate forward regression procedures were under-
taken to identify variables associated with survival using Cox pro-
portional hazards analysis. Subsequently, a multivariate forward
Cox regression model was created and variables shown to most
likely impact survival in the univariate analysis (i.e. P < 0.2) were
entered in the established model in a step-wise fashion. This
process was continued until no further covariates were found to
be significant in the context of the model.
Statistical analyses were performed using STATA 10.1 for
Macintosh (StataCorp LP, College Station, TX, USA). Survival
analysis and related graphics were performed with SPSS Statistics
17.0 for Macintosh (SPSS Inc., Chicago, IL, USA).
Results
Between 1992 and 2007, 91 patients with biliary tree malignancies
underwent attempted curative resection. Demographics, clinical
and pathological factors are shown in Table 1. Peri-operative
factors and short-term outcomes are shown in Table 2.
Table 1 Demographics, clinical and pathological characteristics by anatomical site (denominator given when less than total denominator for
that variable)
Variable Total IHC EHC GBC P
Median (range), n (%) (n = 91) n = 23 n = 46 n = 22
Age (years) 64 (24–92) 61 (48–89) 64 (24–92) 64.5 (24–77) 0.87
Female 49 (53.8%) 12 22 15 0.20
Comorbidities 51 (56.0%) 17 20 14 0.04
Elevated CA19-9 (>35 U/ml) 20/48 4/11 13/29 3/8 0.90
CA19-9, U/ml 24.7 (3.5–8989) 19.9 (9.8–8989) 33 (3.5–8210) 17.8 (8.6–375) 0.60
Size cm 2.5 (0.7–10.5) 6.5 (1–13.5) 2.5 (0.7–8.0) 2.1 (0.7–4.8) <0.001
R0 resection 57 (62.6%) 16 30 11 0.30
Poor differentiation 22 (24.2%) 4 12 6 0.70
Nodal Metastasis 31 (34.1%) 7 16 8 0.90
LVI 26 (28.6%) 4 13 9 0.21
Perineural Invasion 44 (48.3%) 6 31 7 <0.001
IHC, intrahepatic cholangiocarcinomas; EHC, extrahepatic cholangiocarcinoma; GBC, gallbladder carcinomas.
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Median overall survival for all groups was 22.5 months. At the
completion of the follow-up period 63 (69.2%) patients had died.
The median follow-up for those still alive (n = 28) was 39.7 (5.7–
153.3) months. Survival data are shown in Table 3. GBC histology
correlated with the shortest median survival (14.3 months) fol-
lowed by EHC (24.8 months) and IHC (30.4 months), however,
this finding did not meet statistical significance. Univariate and
multivariate analysis confirmed elevated CA19-9 was the only
independent variable to predict poor survival (Table 3). Patients
with elevated CA19-9 had a median survival of 12.0 months com-
pared with 30.4 months in those with low CA19-9 (P = 0.01,
Fig. 1). Neither total nor direct bilirubin reached statistical signifi-
cance as a predictor of survival in the univariate Cox regression
analysis (P = 0.219 and 0.412, respectively). Hence, the two vari-
ables were not included in the final model.
The range of CA19-9-values was 3.52–8989. Out of the patients
with a recorded value of CA19-9, 20 (44.4%) were higher than 35.
The proportion of patients with elevated CA19-9 was not signifi-
cantly different based upon the extent of resection (19.3% vs.
26.5%, P = 0.29). Pre-operative levels of CA19-9 were available in
45 (55%) patients (52% of IHC, 63% of EHC and 41% of GBC).
To assess the effect of missing values in this analysis, we created a
binary variable ‘missing CA19-9’ and repeated the Cox regression
(data not shown). This variable was not significant in the univa-
riate or multivariate analyses. Inclusion of this variable did not
change the variables included in the final model as presented
below. While the coefficient of the only significant variable
(elevated CA19-9) changed based upon the addition of this new
variable, it did not alter its significance.
Discussion
As a result of the rarity of these tumours, there is a paucity of data
in the literature regarding the outcomes of patients undergoing
curative resection for biliary malignancy. These tumours are chal-
lenging to diagnose, and often present at an advanced stage.2,8–10
Hence, accrual of patients that have undergone radical resections
of such malignancies, to allow meaningful analysis, is difficult
even in large volume centres. In the present study, we analysed our
single-institution experience of 91 patients undergoing resection,
with the aim of reporting potential predictors of survival in these
malignancies.
The current study has shown that, in broad terms, the clinico-
pathological characteristics of biliary malignancies are similar.
Biliary tumours tend to present with advanced disease and IHC
typically present with larger size. Attempts at resection reveal
similar proportion of margin-negative resection between the
three tumor types, however, location, tumour stage, and margin
status were not predictive of survival. Elevated CA19-9 appears to
be the only predictor of survival in the patients undergoing resec-
tion irrespective of the bilirubin.
CA19-9 is an antigen directed at circulating glycoproteins that
are coated with sialylated blood group antigens.15,16 CA 19-9 levels
Table 2 Peri-operative characteristics of patients undergoing resection for biliary malignancies
Variable Total IHC EHC GBC P
Median (range), n (%) (n = 91) n = 23 n = 46 n = 22
Primary operation
Liver resection 56 (61.5) 23 18 15 NA
Extrahepatic biliary resection 35 (38.5) 7 28 0 NA
Pancreaticoduodenectomy 18 (19.8) NA 18 NA NA
Complications 16 (18.5) 4 6 6 0.34
Length of stay, days 9 (1–70) 8.5 (1–70) 9 (1–69) 10 (4–41) 0.8
30-day mortality 4 (4.4) 1 2 1 0.6
IHC, intrahepatic cholangiocarcinomas; EHC, extrahepatic cholangiocarcinoma; GBC, gallbladder carcinomas; NA, not applicable.
Table 3 Cox proportional hazards analysis of variables (model
P-value = 0.026)
Variable Median
survival
Univariate
analysis
Multivariate
analysis
(months) P-value P-value
Elevated CA 19-9 (>35 U/ml)
Yes (n = 20) 12.0 0.01 0.017
No (n = 28) 30.4
Poorly differentiated
Yes (n = 22) 22.5 0.449 0.706
No (n = 69) 33.4
Nodal metastasis
N0 (n = 60) 30.3 0.201 0.141
N1 (n = 31) 15.7
R0 resection
R0 (n = 57) 24.8 0.185 0.550
R1 (n = 34) 15.7
Lymphovascular invasion
Yes (n = 26) 17.2 0.158 0.445
No (n = 65) 28.4
Perineural invasion
Yes (n = 44) 22.3 0.416 0.919
No (n = 47) 24.8
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can be elevated in other malignancies such as ovarian, stomach,
pancreas and colon.16 It can also be elevated in any condition
leading to dilation, obstruction or inflammation of the bile ducts
such as benign stricture and cholangitis.15 Many authors have
described an association between elevated CA19-9 and poor out-
comes, in the setting of biliary or other malignancies, using
different value cutoffs, or different measurement techniques.4,17–19
In patients with cholangiocarcinoma a cutoff value of 100 U/ml,
was previously shown to portend a sensitivity and specificity for
detecting cholangiocarcinoma ranging from 53% to 89% and
80% to 91%, respectively.15
Although surgeons are used to seeing extremely high levels,
often in the thousands,4,15,17,18 the current study has shown that
even slightly abnormally elevated levels (>35 U/ml) appear to be
associated with a poorer outcome. To the authors’ knowledge,
CA19-9 has never been linked to outcome post-surgical treatment
of biliary malignancy. In the present study, CA19-9 was the only
predictor of survival: elevated levels arbitrarily set at the upper
limit of normal (>35 U/ml), were identified to be correlated with
poor survival, despite operative resection.
Pre-operative levels of CA19-9 were available in 45 (55%)
patients (52% of IHC, 63% of EHC and 41% of GBC). To assess
the effect of missing values in this analysis, we created a binary
variable ‘missing CA19-9’ and repeated the Cox regression. This
variable was not significant in the univariate or multivariate
analyses. Inclusion of this variable did not change the variables
included in the final model as presented below. While the coeffi-
cient of the only significant variable (elevated CA19-9) changed
based upon the addition of this new variable, it did not alter its
significance. Hence, the final conclusion remains the same. It
remains interesting that within the current study typical predic-
tors of survival described by other authors in the literature (R0
resection, nodal involvement, and lymphovascular involve-
ment),2,3,20 did not predict survival and outcome.
This study has several potential weaknesses. It is a retrospective
cohort review of patients undergoing radical resection. By
design, this study spans 16 years of experience treating these
malignancies. With changing approaches to the resection and
with evolving chemotherapy, there may be an element of lead
time bias – patients treated more recently may be doing better
subsequent to lessons learned from previous experiences, better
approaches to chemotherapy with newer agents and overall
better supportive care. As in the case of most studies evaluating
these tumours, this study may also be underpowered to identify
subtle differences between the three tumour sites evaluated
herein. Despite these potential weaknesses, the effect of elevated
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Figure 1 Cumulative survival by high CA 19-9 levels. Table depicts patients at risk at each time interval
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CA19-9 was pronounced and we recommend considering it prior
to resection.
In summary, while location (i.e. IHC or EHC) is often con-
sidered predictive of survival, the current study did not find a
difference in biological behaviour based upon location or histol-
ogy. Pre-operative CA19-9 was more predictive of survival than
typical histopathological characteristics when radical resection
was possible, suggesting that aggressive surgical resection still be
considered even in the presence of advanced disease. In light of
these findings it is recommended that CA19-9 should be routinely
measured prior to attempted curative resection. This study pro-
vides data that could potentially render CA19-9 a useful stratifi-
cation tool in the setting of future clinical trials assessing the
efficacy of chemotherapy or radiation.
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